Search Results
Apr 20, 2026, 07:00 ET Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
24Abstract Presentation Number: 391In this study, researchers established models primarily resistant to TUSC2 gene therapy (REQORSA or Quar Oze) to find biomarkers indicative of TUSC2 gene therapy resistance in NSCLC cell lines, PDX-derived organoids (PDXOs), and patient-derived xenografts (PDXs). A
More news about: Genprex, Inc.
Apr 20, 2026, 06:07 ET Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
efficacy, and safety in preclinical models of multiple myeloma.In vitro, IMV102 showed highly selective transduction of T cells, achieving efficient gene delivery in Jurkat T-cell lines, while minimal transduction was observed in non-target cells such as hepatocytes and Kupffer cells, indicating strong
More news about: Immunofoco
Apr 20, 2026, 03:05 ET Labbit Goes All-In on LIMS Platform, Retires Semaphore Solutions Brand
product teams to Labbit. The company now operates as a single entity focused on laboratory informatics software for molecular diagnostics, cell and gene therapy, manufacturing quality control, and pharma research and development.Labbit was built by the Semaphore Solutions team, which spent more
More news about: Labbit
Apr 20, 2026, 02:30 ET New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com
More news about: Specialised Therapeutics
Apr 19, 2026, 21:00 ET ACT Genomics nâng cấp xét nghiệm hệ gen được công nhận lâm sàng lên bảng 101 gene với thời gian trả kết quả 7 ngày
More news about: ACT Genomics
Apr 19, 2026, 13:19 ET Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failureVALBY, Denmark, April 19, 2026
More news about: H. Lundbeck A/S
Apr 18, 2026, 22:00 ET 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
Biology is best understood by measuring molecules and cells within intact tissue, where gene expression, cellular states and spatial organization together shape how disease emerges and evolves. Historically, these dimensions have been studied
More news about: 10x Genomics, Inc.
Apr 18, 2026, 19:44 ET BREAKTHROUGH PRIZE ANNOUNCES 2026 LAUREATES
clinical gene therapy expertise proved crucial in the development of the approved drug, including gaining regulatory approval to conduct the initial clinical trials, and in directing the production and characterization of high-quality viral vector preparations used to introduce the replacement gene. The three
More news about: Breakthrough Prize
Apr 18, 2026, 19:01 ET Penn Medicine, Children's Hospital of Philadelphia team awarded Breakthrough Prize for developing gene therapy for inherited blindness
delivering the donated gene into skeletal muscle and the liver.The work was promising, but the human immune response to the gene delivery vessel—which was derived from a virus in the same way Bennett and Maguire's therapy was—prevented sustained benefits from the therapeutic gene. At the same time,
More news about: Children's Hospital of Philadelphia
Apr 17, 2026, 16:31 ET SK Life Science Labs to Present New Preclinical Data on Targeted Protein Degradation at AACR Annual Meeting 2026
durable target modulation.Why is p300 an important target in cancer?p300 is a transcriptional co-activator involved in regulating gene expression in multiple cancers. Selective degradation of p300 enables precise targeting of tumor-driving pathways, particularly in cancers with CBP
More news about: SK Life Science Labs
Apr 17, 2026, 11:00 ET CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
Introducing the first in vivo data using RetroT, a first-in-class all-mRNA platform for stable gene delivery without viral componentsDemonstrating CREATE's leadership in in vivo immune cell engineering across T cells, NK cells, and myeloid cells
More news about: CREATE Medicines, Inc.
Apr 17, 2026, 09:00 ET Parker Institute for Cancer Immunotherapy Network Shapes the Future Of Immunotherapy with Latest Research at AACR Annual Meeting 2026
Abstract 5193)In Vivo Gene Editing & CRISPRAlexander Marson, MD, PhD (Gladstone/UCSF): In vivo genome-wide CRISPR screens in human T cells
More news about: Parker Institute for Cancer Immunotherapy
Apr 17, 2026, 09:00 ET Jiro Egawa, Bobby Hundreds, Lisa Ling, Nanxi Liu, Ally Maki, Thai Nguyen, Vicky Tsai, and Albert Yang to Be Honored at Character Honors
The London West Hollywood, the ceremony will bring together founders, investors, and industry leaders, and will be hosted by Helen Hong and Gene Kang, with a performance by Katherine Ho."Character Honors was created to spotlight the breadth of AAPI leadership shaping the future
More news about: Character Media
Apr 17, 2026, 08:00 ET Ultima Genomics releases groundbreaking TRACERx MRD data showing ppmSeq performance and unveils clinical progress of whole genome sequencing at inaugural global MRD Symposium at AACR 2026
Quantum mechanics-based multi-tensor AI/ML correctly predicts glioblastoma patients' overall survival, gene targets, and treatment response from whole genomesAbout Ultima GenomicsUltima Genomics is unleashing
More news about: Ultima Genomics
Apr 16, 2026, 12:45 ET 'Functional Unemployment' Improves But Wages Down, Says Ludwig Institute
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity
Apr 16, 2026, 11:03 ET /C O R R E C T I O N -- Boehringer Ingelheim/
need for additional treatment options for people living with advanced NSCLC.Up to 4% of lung cancers are driven by HER2 mutations (or gene alterations).3 Mutations in HER2 can lead to overexpression and overactivation, which can in turn result in uncontrolled cell production,
More news about: Boehringer Ingelheim
Apr 16, 2026, 08:59 ET Quintara Biosciences Introduces AmpValue: $4.99 Full-Length Nanopore Amplicon Sequencing
of traditional Sanger sequencing by easily resolving primer dependency issues and complex secondary structures like hairpins.CRISPR and Gene Editing Analysis: Provides full-length interrogation of genomic loci to accurately characterize indels and mixed allele populations in heterozygous
More news about: Quintara Biosciences
Apr 16, 2026, 08:30 ET GREENLAND MINES ENTERS INTO LOI TO EVALUATE BROWNFIELD DOWNSTREAM ICELANDIC INDUSTRIAL PROCESSING SITE, OUTLINES STRATEGIC SUPPLY CHAIN SECURITY PROGRAM
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80%
More news about: Greenland Mines Ltd
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows.Bio-Techne Spatial: Empowering Better Answers in Translational Research The Bio-Techne Spatial1 portfolio
More news about: Bio-Techne Corporation
Apr 16, 2026, 06:16 ET ATUM Appoints Industry Veteran Gavin Barnard, Ph.D., as Chief Scientific Officer
therapies into the clinic."About ATUMATUM is a fully integrated biotechnology contract research organization that provides services for gene design, protein engineering, and cell line development. By combining machine learning, synthetic biology, and proprietary expression technologies, ATUM
More news about: ATUM
Apr 16, 2026, 03:07 ET BIO Asia-Taiwan 2026 to Be Held in Mid-July in Taipei
companies such as Alar Pharmaceuticals and Pharmosa Biopharm have secured licensing deals worth hundreds of millions of US dollars. A recently approved gene therapy for AADC deficiency developed by NTU Hospital, serves as a model for translating academic research into commercialized therapies. Additionally,
More news about: Taiwan Bio Industry Organization
Apr 15, 2026, 15:26 ET Seragon Publishes Data for Longevity Drug SRN-901 Showing Significant Lifespan and Healthspan Extension
placebo-treated mice. Transcriptomic Modulation of Aging Pathways: Transcriptomic analyses revealed that SRN-901 modulates gene expression across pathways implicated in aging biology. Pathways related to DNA repair were upregulated in the SRN-901 treated mice. Conversely, pathways
More news about: Seragon Biosciences
Apr 15, 2026, 13:33 ET TEDCO's Maryland Innovation Initiative Announces More Than $2.1M to Latest Awardees
aquatic biological samples; Johns Hopkins University; received $300,000Aletira Therapeutics, Inc. - Next generation gene therapy to prevent the most common form of hereditary hearing loss; Johns Hopkins University; received $300,000The Technology Assessment
More news about: TEDCO